HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Significant correlation of peptidyl-prolyl isomerase overexpression in Merkel cell carcinoma with overall survival of patients.

AbstractBACKGROUND:
An overexpression of PIN1, the peptidyl-prolyl cis-trans isomerase, might cause cell cycle arrest and growth inhibition by binding to the p53 protein, a process leading to p53 stabilization. The rationale of this retrospective analysis was to evaluate the expression pattern of PIN1 in Merkel cell carcinomas (MCCs) and its suitability as a prognostic factor.
METHODS:
Samples of 27 MCCs were immunhistochemically stained for PIN1 expression and correlated with overall and disease-free survival of patients.
RESULTS:
All samples expressed PIN1. We showed a significantly better overall survival in patients with an overexpression of PIN1 than in patients with a weak PIN1 expression (p = .031), but expression was not significant for disease-free survival (p = .821). The 5-year overall survival rate was 14.4% in patients with weak and 50.9% in patients with overexpression of PIN1.
CONCLUSIONS:
PIN1 seems to be a prognostic factor for a better overall survival rate of patients with MCC.
AuthorsClaudia Lill, Sven Schneider, Johannes Pammer, Robert Loewe, Wilhelm Gedlicka, Roland Houben, Gregor Heiduschka, Markus Brunner, Dietmar Thurnher
JournalHead & neck (Head Neck) Vol. 33 Issue 9 Pg. 1294-300 (Sep 2011) ISSN: 1097-0347 [Electronic] United States
PMID21837699 (Publication Type: Journal Article)
CopyrightCopyright © 2010 Wiley Periodicals, Inc.
Chemical References
  • NIMA-Interacting Peptidylprolyl Isomerase
  • PIN1 protein, human
  • Peptidylprolyl Isomerase
Topics
  • Aged
  • Aged, 80 and over
  • Carcinoma, Merkel Cell (enzymology, mortality, pathology)
  • Female
  • Humans
  • Immunohistochemistry
  • Male
  • Middle Aged
  • NIMA-Interacting Peptidylprolyl Isomerase
  • Peptidylprolyl Isomerase (metabolism)
  • Prognosis
  • Retrospective Studies
  • Skin Neoplasms (enzymology, mortality, pathology)
  • Survival Analysis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: